DOCTO, CHRISTIAN DAVE

ESCABARTE, CANE

May 23, 2016

LEPROSY CONTROL PROGRAM

Vision: Empowered primary stakeholders in leprosy and eliminated leprosy as a public health problem
by 2020
Mission: To ensure the provision of a comprehensive, integrated quality leprosy services at all levels of
health care
Goal: To maintain and sustain the elimination status
Objectives:
The National Leprosy Control Program aims to:

Ensure the availability of adequate anti-leprosy drugs or multiple drug therapy (MDT).
Prevent and reduce disabilities from leprosy by 35% through Rehabilitation and Prevention of
Impairments and Disabilities (RPIOD) and SelfCare.
Improve case detection and post-elimination surveillance system using the WHO protocol in
selected LGUs.
Integration of leprosy control with other health services at the local level.
Active participation of person affected by leprosy in leprosy control and human dignity
program in collaboration with the National Program for Persons with Disability.
Strengthen the collaboration with partners and other stakeholders in the provision of quality
leprosy services for socio-economic mobilization and advocacy activities for leprosy.

Beneficiaries:
The NLCP targets individuals, families, and communities living in hyperendemic areas and those with
history of previous cases.
NLCP Strategy
(2011-2016)
MDG& NOH

Global Strategy
(2006-2010)

Sustain leprosy
control in all
endemic countries

Strengthen
routine & referral
service

Ensure high
quality diagnosis,

Provision of
Quality Leprosy
services at all
levels

Universal Health Care

(Kalusugang
Pangkalahatan)

Governance for
Health

Health System
Strengthening

Service
Delivery

Capability building
of an efficient,

Policy,
Standards &

case management,
recording &
reporting in all
endemic
communities

Establish the
Sentinel Surveilla
nce System to
monitor Drug
Resistance

Develop
procedures/ tools
that are
home/communitybased, integrated
and locally
appropriate for
Self Care/POD,
rehabilitation
services (CBR)

effective,
accessible human
and facility
resources

Develop policies/
guidelines/ sentinel
sites/referral
centers
(Luzon,Visayas &
Mindanao)

Collaborate with
NEC/RESU/ PESU
/ MESU

NLAB, NCCL

RA 7277- Rights of
PWD & Caregivers

BP 34Accessibility &
Human Rights Law

PhilHealth
Insurance Package

Regulations

Human
Resources for
Health

Health
Information

Health
Financing

Background:

When the DOH established its National Leprosy Control Program (NLCP) in 1986, there were
38,570 registered leprosy patients in the country, translating to an annual prevalence rate of 7.2
per 10,000 Filipinos.

By the end of 1998, leprosy was virtually eliminated as a public health problem, in response to
the World Health Organization-World Health Assembly call to eliminate leprosy in 2000. This
level has been sustained up to the present. However, there are still pockets of cases identified in
some municipalities in the country.

Higher cases found to be reported in Regions 1, 7 and 12.

At present, the prevalence rate is pegged at 0.2 per 10,000 population and this is equivalent to
1,000 to 2,000 new infections every year.

Dr. Francesca Gajete, program manager of DOH-NLCP, said the reduction in leprosy cases was
primarily caused by the development of multi-drug therapy (MDT), a cocktail of three drugs that
made the disease curable. Dapsone, rifampicin and clofazimine were developed by Novartis.

http://www.doh.gov.ph/leprosy-control-program